RJ Hamster
Wall Street Is Warming Up to Health Care Again
You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here.
Prefer to view this content on our website? Click here.
Dear Fellow Investor,
Health Care’s Quiet Rotation Is Broadening: 3 Stocks Positioned to Benefit
Health care is quietly stepping back into the spotlight, and the most interesting part is that it is not behaving like a purely defensive trade.
Yes, health care has historically served as a steadier corner of the market during periods of uncertainty. But the recent shift has a different feel: the sector has flashed a rare historical signal, one that has not appeared often over the last few decades. When this type of setup has emerged in prior cycles, health care has often gone on to deliver meaningful relative outperformance.
The second notable detail is how the move has developed. For much of the year, gains were concentrated in a relatively small cluster of high-quality leaders, exactly the kind of narrow participation that can make a sector rally look stronger than it really is. Narrow leadership can persist, but it is also vulnerable: if the leaders stall, the entire theme can fade quickly.
That is why the current phase matters. What began as a “stealth rotation” is now broadening. More companies are joining the uptrend, and investor attention is expanding from a handful of familiar winners to a deeper bench across the industry. In market terms, improving breadth is often what turns a short-lived move into a more durable trend because it suggests the bid is not reliant on one or two names carrying the whole group.
For long-term investors, this kind of broadening can be a meaningful tell. When participation improves, it can indicate that the market is starting to price in better fundamentals across the sector: stabilizing demand, a more constructive earnings outlook, improving visibility, or even a shift in how investors value cash flows. And in health care specifically, broadening participation can also reflect a rotation toward businesses with recurring demand drivers that are less sensitive to the economic cycle.
With that backdrop, here is a look at three health care stocks that appear well positioned to benefit from a stronger, broader sector tape – supported by buy ratings from major firms and constructive implied upside to price targets.
Company: Agilent Technologies (SYM: A)
Picks-and-shovels exposure to life sciences and diagnostics
Recent Price: $141.74
Price Target: $168.08
Firms with Buy Rating: Morgan Stanley, Goldman Sachs, UBS
Agilent operates as an applications-focused provider to the life sciences, diagnostics, and applied chemical markets. Its business spans three segments, Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab, giving it broad exposure to the tools and services that support research, testing, and clinical workflows.
From an investor perspective, Agilent is often viewed as a “picks-and-shovels” way to participate in long-run health care and biotech innovation. Instead of betting on the success of a single drug, it sells essential instruments, consumables, and services that are used across many customers and end markets. In many cycles, that positioning can translate into a more resilient demand profile, especially when the company has a meaningful installed base and recurring service or consumables revenue.
Why might it benefit as the rotation broadens? When breadth improves in health care, it is often because investors are looking beyond headline drug makers and into the ecosystem that supports the entire innovation pipeline. As confidence improves around research activity, diagnostics demand, or clinical testing volumes, the market frequently re-rates the enabling platforms that sit behind the scenes.
Analyst support from multiple major firms suggests confidence in the company’s ability to execute through the next phase. The implied upside to target also indicates that, even after recent strength in parts of health care, some on the Street still see valuation room if fundamentals and sentiment continue to firm.
What to watch into 2026: order trends, lab spending cycles, and whether the mix continues to favor higher-value workflow solutions, factors that can influence both growth and margin structure.
Trading Whisperer
Wall Street’s New ETF Targets Global Money Movement
Money movement is changing faster than anyone expected.
Data centers run 24 hours. E-commerce runs 24 hours. Now finance is racing to catch up.
A newly listed ETF just opened the door to that evolution, offering a direct play on instant settlement through a simple, US listed wrapper.
Second-level finality. Institutional custody.
You trade it like any other fund. It reports like any other fund.
And while others chase hype, this product is built for discipline. Single asset exposure, no leverage, no hidden overlays, and a clear 0.50% sponsor fee.*
Every previous digital-asset ETF proved the appetite. Strong volume. Rapid AUM. A growing share of portfolios that used to avoid the space entirely.
This one brings that same structure to the payments side, the part of finance where efficiency actually pays.
The window to get in early is open. Learn more now.
Get the symbol before the crowd.
Company: AbbVie (SYM: ABBV)
A scale biopharma story with multiple franchises
Recent Price: $223.58
Price Target: $248.67
Firms with Buy Rating: HSBC, Piper Sandler, J.P. Morgan
AbbVie is a research-based biopharmaceutical company with a broad global portfolio spanning immunology, oncology, neuroscience, eye care, virology, and more. Investors most commonly associate AbbVie with major immunology therapies, historically Humira and, increasingly, newer therapies such as Skyrizi and Rinvoq, alongside a wide set of other branded medicines and aesthetics products.
In a broadening health care tape, AbbVie can stand out for a different reason than tools companies: it combines scale, cash flow, and diversified end markets. When investors re-engage with health care beyond the “defensive” framing, large, profitable biopharma companies with multiple growth drivers and strong commercial execution often re-enter the conversation as core holdings, not just tactical positions.
The appeal is typically a blend of durability and optionality:
- Durability because demand for many therapies is not tightly linked to GDP growth.
- Optionality because successful drug franchises, label expansions, and pipeline progress can create upside that is not always reflected in near-term numbers.
Analyst buy ratings across multiple firms suggest a constructive outlook on AbbVie’s ability to sustain performance as its portfolio evolves. The gap between the recent price and target is not extreme, but it still implies further upside if execution and earnings visibility remain strong.
What to watch into 2026: continued performance across key franchises, competitive dynamics in major therapeutic areas, and any pipeline catalysts that could expand the company’s growth profile.
Crypto 101
Get in before the new year rally hits
Let me tell you something about memecoins…when they move, they move FAST.
We’re not talking about slow, steady 20% gains over months. We’re talking about:
→ 600% in a single day
→ 1,100% in 48 hours
→ 8,200% in 5 months
That’s the kind of speed we’ve seen from my analysts Brian and Joe, who have developed a system for identifying memecoins before they explode.
The market is oversold. Fear is everywhere. Most investors are sitting on the sidelines waiting for “confirmation.”
But January has historically been one of crypto’s strongest months. A new year rally could be building as we speak. And when momentum returns to the market, memecoins don’t just participate…they lead.
Brian and Joe just flagged their #1 memecoin for January 2026. It’s still trading for pennies. It has viral energy, real utility, and a capped supply with a burn mechanism built in.
You can get the full report—what the coin is, how to buy it, and exactly what to expect—right now:
Get the #1 Memecoin for January 2026 here
Company: Thermo Fisher Scientific (SYM: TMO)
A category leader across the life science stack
Recent Price: $567.36
Price Target: $631.80
Firms with Buy Rating: Goldman Sachs, Morgan Stanley, Barclays
Thermo Fisher is one of the most strategically important companies in the life sciences ecosystem. It provides solutions across analytical instruments, specialty diagnostics, lab products, and biopharma services, selling everything from research consumables to sophisticated instrumentation and services supporting drug development and manufacturing.
Thermo Fisher’s breadth matters. In a sector rotation that is broadening, businesses with multiple demand drivers can be especially attractive because they are not dependent on one narrow pocket of the industry. The company’s segments span research and discovery, clinical and diagnostic testing, and bioproduction services, areas that can take turns leading depending on the cycle.
Analysts who like Thermo Fisher often point to a few structural strengths:
- Scale and customer reach: It is embedded across pharma, biotech, academia, government, and industrial markets.
- Recurring demand: Many product categories are consumables- or service-heavy, supporting repeat purchases.
- Strategic positioning in biopharma services:Outsourcing trends and the complexity of biologics manufacturing can support long-run demand for specialized capabilities.
The implied upside to the target suggests analysts see room for appreciation if the market continues to reward health care “infrastructure” businesses as the rotation widens.
What to watch into 2026: biopharma funding and production trends, research activity levels, and how management balances growth and margin priorities across segments.
Paradigm Press
This Backdoor Play on Starlink’s IPO for Less than $100?Whenever Elon Musk goes “all in” on something, it always generates HUGE excitement and opportunity.
His latest project, Starlink – with its mission to provide satellite Internet to every corner of the globe – is no exception.
And one man says it will soon go public, at an estimated $100 BILLION valuation.
That would make it the biggest IPO in HISTORY…
Roughly 228X BIGGER than Amazon’s IPO.
Today, investing legend James Altucher has uncovered a smart, unconventional way to potentially benefit from the impending Starlink IPO…
This backdoor play lets savvy investors like you engage with Starlink’s promise without the need for direct initial IPO access.
What other stocks do you have your eye on heading into 2026? What other sectors of the market are you currently interested in? Hit “reply” to this email and let us know your thoughts!
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Canary XRP ETF (NASDAQ:XRPC). The compensation consists of up to $6,500 and was received/will be received from Market Jar Media.
This communication should not be considered as an endorsement of the securities of adviser Canary XRP ETF (NASDAQ:XRPC) and we are not responsible for any errors or omissions in any information provided about the securities of Canary XRP ETF (NASDAQ:XRPC) by Trading Whisperer or Market Jar Media.
We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.
This disclosure is made as of 12/29/25.
*Brokerage commissions apply and will reduce returns
For standardized returns of the Canary XRP ETF, please visit [XRP ETF – Canary Capital]. Past performance does not guarantee future results.
The Fund’s investment objectives, risks, charges and expenses should be considered before investing.
The prospectus contains this and other important information, and it may be obtained at https://etfs.canary.capital/XRPC/prospectus/. Read it carefully before investing.
The Fund is not an investment company registered under the Investment Company Act of 1940 (the “1940 Act”), and therefore is not subject to the same regulatory requirements as mutual funds or traditional ETFs registered under the 1940 Act.
Investing Involves Significant Risk. The loss of principal is possible. Canary XRP ETF (the “Fund”) may not be suitable for all investors. This document does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial advisor/financial consultant before making any investment decisions.
The fund is new with a limited operating history.
Digital assets, such as XRP, are a relatively new asset class, and the market for digital assets is subject to rapid changes and uncertainty. Digital assets are largely unregulated and digital asset investments may be more susceptible to fraud and manipulation than more regulated investments.
XRP is subject to unique and substantial risks, including significant price volatility and lack of liquidity, and theft. The value of an investment in the Fund could decline significantly and without warning, including to zero. XRP is subject to rapid price swings, including as a result of actions and statements by influencers and the media, changes in the supply of and demand for digital assets, and other factors. There is no assurance that XRP will maintain its value over the long-term. The Fund is not actively managed and will not take any actions to take advantage, or mitigate the impacts, of volatility in the price of XRP. An investment in the Fund is not a direct investment in XRP. Investors will not have any rights that XRP holders have and will not have the right to receive any redemption proceeds in XRP. Shares of the Fund are generally bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Only Authorized Participants may trade directly with the Fund and only large blocks of Shares called “creation units.” Your brokerage commissions will reduce returns.
Paralel Distributors LLC serves as the marketing agent. Paralel is unaffiliated with Canary Capital and Native Ads.
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You’re receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
